Kevin Grimes, MD
Infectious Disease · Houston, TXNPI 1023137494
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $720 of the $784 with a category attached, or 91.8%. AbbVie accounts for 91.8% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $720 and has fallen 95.1% since, to $35 in 2024.
Across 3 payments — averaging $261.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$720
- Astellas Pharma US Inc$64
Across 14 payments — averaging $136,067 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$1.9M
What the payments were for
- Consulting fees$72092%
- Education$648%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $720 |
| Astellas Pharma US Inc | 2 | $64 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEFLARO$720
How this compares
$784 in reported general payments places this provider in the 55th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 105 | $419,152 |
| JulucaDolutegravir/Rilpivirine | 56 | $192,349 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 46 | $177,613 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 38 | $135,396 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $36,252 |
| XeravaEravacycline Di-Hydrochloride | 12 | $8,912 |
| ErtapenemErtapenem Sodium | 12 | $3,974 |
| Cefepime Hcl | 13 | $3,950 |
| Ceftazidime | 13 | $2,387 |
| Voriconazole | 18 | $1,529 |
| ValacyclovirValacyclovir Hcl | 17 | $992 |
| Valganciclovir Hcl | 12 | $852 |
| Fluconazole | 16 | $782 |
| Doxycycline Hyclate | 11 | $696 |
| Cefazolin Sodium | 11 | $454 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Houston
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Ben BarnettHouston$424K
- Amar SafdarHouston$284K
- Luis OstroskyHouston$173K
- Richard HamillHouston$137K
- Karen VigilHouston$91K
- John RexHouston$63K
- Pablo OkhuysenHouston$57K
- Rodrigo HasbunHouston$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.